Lenovo Becomes Global Partner of Formula 1® in Renewed Deal
Formula 1® and Lenovo have today announced the extension of its partnership that will see the technology giant elevated to a Global Partner in a multi-year renewal starting from the beginning of 2025. As part of the deal, Motorola, a subsidiary of Lenovo Group, will become Global Smartphone Partner of F1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905029431/en/
(Photo: Business Wire)
As a Global Partner of Formula 1, Lenovo will continue to provide F1 with state-of-the-art technology devices, solutions and services to support the delivery of Grands Prix at track and remotely. Under the agreement, Lenovo will serve as the title sponsor for two races per season and Lenovo and Motorola will have increased trackside branding at events.
Since 2022, Lenovo technology has been at the heart of F1’s operations as an Official Partner. Through its on-site High-Performance Computing (HPC) solutions, servers and edge devices, Lenovo has been supporting Formula 1 in its delivery of its best-in-class broadcast product, bringing the drama and excitement of F1 to millions of fans around the world, with a truly global team that’s always-on. Lenovo hardware – including laptops, workstations, desktop computers and monitors, as well as tablets and Motorola smartphones – provide F1 staff with high-quality equipment to create engaging, customised content for the sport’s ever expanding and passionate fanbase.
Additionally, Lenovo’s Asset Recovery Service supports F1’s wider sustainability strategy, alongside its efforts to reduce emissions and reach Net Zero by 2030. Lenovo’s Asset Recovery Service helps ensure that retired computing hardware is recycled in a socially and environmentally conscious manner. Since the beginning of the partnership, F1 has sustainably disposed 95% of obsolete hardware, which ultimately helps to reduce costs and mitigate security risks through reliable data destruction with enhanced security.
Throughout the partnership, Lenovo has aimed to integrate smarter technology into the sport. The world’s first kiss-activated trophies at the FORMULA 1 LENOVO JAPANESE GRAND PRIX 2023 and FORMULA 1 LENOVO UNITED STATES GRAND PRIX 2023, along with this year’s laurel wreath design, combining tradition and innovation, elevated the podium celebrations and serve as strong symbols of Lenovo’s drive for purposeful design and cutting-edge technology.
In recent years, F1 has seen a significant growth in popularity, with increased television audiences, record attendance and fan engagement across all platforms. Both F1 and Lenovo share a commitment to sustainability and the exploration of next generation technologies, like Lenovo AI PCs, AI-enabled Motorola smartphones and AR/VR solutions.
Through direct collaboration between F1’s technical teams and Lenovo’s Centres of Excellence, highly innovative solutions are being found to a variety of challenges, such as the use of onsite and Edge Compute AI solutions to improve operational efficiency during live F1 broadcasts. Together, F1 and Lenovo will continue to build on years of successful collaboration to develop the future of the sport.
Stefano Domenicali, CEO and President of Formula 1 said:
“I am delighted that Lenovo will become a Global Partner of Formula 1. Since joining the sport Lenovo’s creativity and passion for technology and innovation have supported F1’s ambitions to create more once-in-a-lifetime moments for fans. Today marks a new chapter in a partnership that will only continue to grow from strength to strength. I look forward to continuing our work with Lenovo and using our shared commitment to precision, innovation, and sustainability to ensure F1 remains the world’s most technologically advanced sport for years to come.”
Yang Yuanqing, Chairman & CEO of Lenovo, said:
"We are thrilled to elevate our partnership to the next level becoming a Global Partner of Formula 1. Our vision at Lenovo is to harness the power of AI to create a smarter, more inclusive, and sustainable world, accessible to everyone. Through our groundbreaking partnerships, like the one with Formula 1, we are pushing the boundaries of innovation and performance. Together, we’re not just shaping the future of technology and motorsport, but we’re also ensuring that cutting-edge technological advancements benefit all, creating unforgettable experiences no matter where they are in the world."
Luca Rossi, President of Intelligent Devices Group, Lenovo, said:
“When we embarked on our journey with F1 three years ago, we knew they were the right partner for Lenovo as our brand values seamlessly aligned for a smarter, faster, and more sustainable future. Seeing our high-performance technology implemented across every level of the F1 organization fills us with pride, and our close collaboration together has just begun. We look forward to taking our partnership to newer heights and continue having Lenovo’s AI-ready hardware, as well as our solutions and services, transform and benefit the fan experience worldwide.”
About Formula 1®
Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: LSXMA, LSXMB, LSXMK, FWONA, FWONK, LLYVA, LLVYK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905029431/en/
Contacts
Formula 1 Press Office
Formula 1 Press Office
E: f1media@f1.com
T: @f1media
Note: If you no longer wish to receive these emails, please write to f1media@f1.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom